# Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae

> **NCT02583373** · PHASE1 · COMPLETED · sponsor: **Combioxin SA** · enrollment: 19 (actual)

## Conditions studied

- Pneumonia
- Pneumococcal Infections

## Interventions

- **DRUG:** CAL02 Low-dose
- **DRUG:** CAL02 High-dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02583373
- **Lead sponsor:** Combioxin SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-21
- **Primary completion:** 2018-02-20
- **Final completion:** 2018-02-20
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583373, "Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT02583373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*